Histoplasmosis by<i> Histoplasma capsulatum</i> var. duboisii Observed at the Laboratory of Pathological Anatomy of Lomé in Togo

Darré, Tchin; Saka, Bayaki; Mouhari-Touré, A.; Dorkenoo, Améyo Monique; Amégbor, Koffi; Pitché, Vincent Palokinam; Napo‐Koura, Gado

doi:10.1155/2017/2323412

Cited by 25 publications

(34 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 3 ] The literature is not consistent about gender predilection with some authors reporting male predominance, whereas other suggested female preponderance. [ 4 6 ]…”

Section: Discussionmentioning

confidence: 99%

“…In fact, of the 17 cases in a series from Togo, all but four cases (three in patients with AIDS and one case associated with tuberculosis) were in immunocompetent persons. [ 6 ]…”

Section: Discussionmentioning

confidence: 99%

“…This picture is said to be quite classical and allows a reliable diagnosis even without mycological culture. [ 6 ]…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Histoplasma duboisii of the femoral bone

et al. 2019

View full text Add to dashboard Cite

“…[ 3 ] The literature is not consistent about gender predilection with some authors reporting male predominance, whereas other suggested female preponderance. [ 4 6 ]…”

Section: Discussionmentioning

confidence: 99%

“…In fact, of the 17 cases in a series from Togo, all but four cases (three in patients with AIDS and one case associated with tuberculosis) were in immunocompetent persons. [ 6 ]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histoplasma duboisii of the femoral bone

et al. 2019

View full text Add to dashboard Cite

“…are also endemic in regions of Asia and Oceania, but the range is not clearly defined [82][83][84]. The geographical range for H. capsulatum var duboisii does not appear to extend beyond Africa, and overlaps with that of H. capsulatum var capsulatum in regions of endemicity [85,86].…”

Section: Histoplasmamentioning

confidence: 99%

How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts

Denham

Wambaugh

Brown

2019

Journal of Molecular Biology

View full text Add to dashboard Cite

Life-threatening infections in immunocompetent individuals have been documented for all the fungi we discuss. However, the majority of life-threatening infections typically present in individuals with particular immunocompromising risk factors [4]. Thus, the outcome of infection is determined by a constellation of fungal traits and host susceptibilities (Table 1). In this review, we discuss host and fungal factors that contribute to infectivity, persistence within the host, and progression to life-threatening infections for five groups of fungi: Cryptococcus, Aspergillus, Histoplasma, Blastomyces, and Coccidioides spp. These common environmental fungi do not require an infectious life cycle for their survival. They are not transmissible between humans, nor are humans considered a particularly suitable niche for commensalism, such as it is for certain Candida spp. [10]. We do not discuss Candida spp., which are addressed elsewhere in this issue. Aspergillus spp. and Cryptococcus spp. are considered some of the more cosmopolitan fungal species. Due to their large geographical range, respiratory exposure to these fungi is commonplace [11]. Aspergillus spp. commonly cause both asymptomatic and symptomatic 2

show abstract

“…duboisii, is rarely described in HIV infected patients in Africa (African histoplasmosis). 13,14 It was estimated that annual incidence of disseminated histoplasmosis was~100,000 cases globally in 2017. 15 The estimated incidence of histoplasmosis in 2012 was 1.48 cases per 100 people living with HIV in Latin America.…”

Section: Introductionmentioning

confidence: 99%

<p>HIV-Associated Histoplasmosis: Current Perspectives</p>

Myint¹,

Leedy²,

Cari³

et al. 2020

HIV

View full text Add to dashboard Cite

Histoplasmosis is an endemic mycosis caused by Histoplasma capsulatum. Infection develops by inhalation of microconidia from environmental sites inhabited by birds and bats. Disseminated disease is the usual presentation due to impaired cellular immunity. Common clinical manifestations include fever, fatigue, malaise, anorexia, weight loss, and respiratory symptoms. Histoplasma antigen detection is the most sensitive method for diagnosis. The sensitivity of the MVista ® Quantitative Histoplasma antigen enzyme immunoassay is 95-100% in urine, over 90% in serum and bronchoalveolar lavage (BAL) antigen and 78% in cerebral spinal fluid (CSF). A proven diagnosis can be established by culture or pathology with sensitivities between 70% and 80%. The sensitivity of antibody detection by immunodiffusion or complement fixation was between 60% and 70%. Diagnosis using molecular methods has not been adequately validated for implementation and FDA cleared assays are unavailable. Liposomal amphotericin B should be used for 1-2 weeks followed by itraconazole for at least one year until CD4 counts are above 150 cells/mm3, HIV viral load is below 400 copies/mL and Histoplasma urine antigen is negative. Serum itraconazole level should be monitored to avoid drug toxicity. Antigen should be measured periodically to establish that treatment is effective and to assist in identifying relapse. The incidence of immune reconstitution inflammatory syndrome is low but it must be considered in patients who are thought to be failing antifungal treatment as it does not respond to changing antifungal agents but rather to initiation of corticosteroid therapy. In this review, we discuss pathogenesis, clinical manifestations, diagnosis and treatment based on personal experience and relevant publications.

show abstract

Histoplasmosis by Histoplasma capsulatum var. duboisii Observed at the Laboratory of Pathological Anatomy of Lomé in Togo

Cited by 25 publications

References 10 publications

Histoplasma duboisii of the femoral bone

Histoplasma duboisii of the femoral bone

How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts

<p>HIV-Associated Histoplasmosis: Current Perspectives</p>

Contact Info

Product

Resources

About